SynthesisPhytotherapy research : PTR2025
The Impact of Okra (Abelmoschus esculentus) Supplementation on Diabetes and Obesity Biomarkers in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Okra (Abelmoschus esculentus) Supplementation on Diabetes and Obesity Biomarkers in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Phytotherapy research : PTR · 2025Pooled it
- Investigating the Impact ofPlants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Conflicting results have been reported regarding the effects of okra on diabetes biomarkers in patients with type 2 diabetes. These inconsistencies may stem from factors such as dosage, intervention duration, and study design. To address these discrepancies, this systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effects of okra ( Abelmoschus esculentus ) supplementation on diabetes and obesity markers in patients with type 2 diabetes. Relevant studies published up to July 15, 2024, were identified through comprehensive searches in databases including Scopus, Web of Science, PubMed/Medline, and Embase. Studies were included if they assessed the effects of okra supplementation on diabetes and obesity biomarkers in patients with type 2 diabetes. A random-effects model was employed to calculate effect sizes, reported as weighted mean differences (WMD) with 95% confidence intervals (CI). A total of six eligible RCTs was included in the final analysis. The meta-analysis revealed that okra supplementation significantly reduced fasting blood glucose (FBG) (WMD: -21.72 mg/dL, 95% CI: -36.86 to -6.58, p = 0.005) and glycated hemoglobin (HbA1c) levels (WMD: -0.42%, 95% CI: -0.64 to -0.19, p < 0.001). However, no significant effects were observed on insulin levels (WMD: 0.54 μU/mL, 95% CI: -1.03 to 2.12, p = 0.498), insulin resistance as assessed by HOMA-IR (WMD: -0.31, 95% CI: -1.37 to 0.75, p = 0.566), body mass index (BMI) (WMD: -0.24 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.